Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: May 2, 2024
Open Peer Review Period: May 2, 2024 - May 22, 2024
Date Accepted: Feb 4, 2025
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Digital Therapeutics–Based Cardio-Oncology Rehabilitation for Lung Cancer Survivors: Randomized Controlled Trial

Li G, Zhou X, Deng J, Wang J, Ai P, Zeng J, Liao H, Ma X

Digital Therapeutics–Based Cardio-Oncology Rehabilitation for Lung Cancer Survivors: Randomized Controlled Trial

JMIR Mhealth Uhealth 2025;13:e60115

DOI: 10.2196/60115

PMID: 39999435

PMCID: 11897676

DTx-based cardio-oncology rehabilitation for lung cancer survivors: a randomized controlled trial

  • Guangqi Li; 
  • Xueyan Zhou; 
  • Junyue Deng; 
  • Jiao Wang; 
  • Ping Ai; 
  • Jingyuan Zeng; 
  • Hu Liao; 
  • Xuelei Ma

ABSTRACT

Background:

For lung cancer survivors, cardiopulmonary fitness is a strong independent predictor of survival. Home-based cardiac telerehabilitation through wearable devices and mobile apps is a substitution for traditional center-based rehabilitation with equal efficacy and a higher completion rate. However, it has not been widely used in clinical practice.

Objective:

Early-stage non-small cell lung cancer survivors aged 18-70 years. All the participants received surgery 1-2 months before enrollment and did not require further antitumor therapy.

Methods:

Participants were randomized to receive cardiac telerehabilitation or usual care for 5 months. AI-driven exercise prescription with video guide & real-time HR monitoring was generated based on cardiopulmonary exercise testing and optimized dynamically. Outcome measurements included cardiopulmonary fitness, lung function, cardiac function, tumor marker, safety, compliance, and scales assessing symptoms, psychology, sleep, fatigue, and quality of life.

Results:

Forty of 47 patients (85%) finished the trial. The average prescription compliance rate of patients in the telerehabilitation group reached 101.2%, with an average exercise duration of 151.4 min per week and an average effective exercise duration of 92.3 min per week. The cardiac telerehabilitation was associated with higher improvement of VO2peak (3.66±3.23 mL/Kg/min vs 1.09±3.23 mL/Kg/min, p=0.02) and global health status/QOL (16.25±23.02 vs 1.04±13.90, p=0.03) compared with usual care. Better alleviation of affective interference (-0.88±1.50 vs 0.21±1.22, p=0.048), fatigue (-8.89±15.96 vs 1.39±12.09, p=0.02), anxiety (-0.31±0.44 vs -0.05±0.29, p=0.048), and daytime dysfunction (-0.55±0.69 vs 0.00±0.52, p=0.02) were also observed in the telerehabilitation group. No exercise-related adverse events were identified during the intervention period.

Conclusions:

Cardio-oncology telerehabilitation improved cardiorespiratory fitness and quality of life in lung cancer survivors with good compliance and safety. Clinical Trial: chictr.org.cn ChiCTR2200064000


 Citation

Please cite as:

Li G, Zhou X, Deng J, Wang J, Ai P, Zeng J, Liao H, Ma X

Digital Therapeutics–Based Cardio-Oncology Rehabilitation for Lung Cancer Survivors: Randomized Controlled Trial

JMIR Mhealth Uhealth 2025;13:e60115

DOI: 10.2196/60115

PMID: 39999435

PMCID: 11897676

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.